Trial Profile
A Phase 1 Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Subjects With Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 13 Apr 2023 Planned End Date changed from 31 Mar 2023 to 30 Jun 2024.
- 26 Apr 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.
- 15 Aug 2019 Planned End Date changed from 30 Dec 2020 to 31 Mar 2022.